Guy Regev Director Stock Option Holdings in Can-Fite BioPharma

This Form 3 filing discloses initial stock ownership and derivative holdings of Guy Regev, a director of Can-Fite BioPharma Ltd. The filing reports Regev's ownership of 8 ordinary shares and multiple option grants to purchase additional shares. The options include: 16 options from 2017 with a $2,826.14 exercise price expiring 2027; 200 options from 2020 at $241.47 expiring 2030; 2,166 options from 2023 at $25.21 expiring 2033; 2,166 options from 2024 at $26.56 expiring 2034; and 16,000 options from 2026 at $2.18 expiring 2030. Many options have vesting schedules extending through 2028-2030. The filing notes that options are held through a trustee for Israeli tax benefits and exercise prices were originally denominated in New Israeli Shekels but converted to USD.